Latest News and Press Releases

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance...

Los Angeles Dianetics volunteers joined a global outreach offering Dianetics and free stress tests to raise awareness and close out Mental Health Awareness

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as CMO to advance FMP374 toward the clinic in treatment-resistant depression.

As stress, anxiety and depression remain widespread, Dianetics has helped many to understand the mind and address the source of unwanted emotions.

Facing economic and financial pressure, new research shows that young men and fathers are at significantly higher risk of problem gambling.

Entrepreneurs, athletes and musicians discuss how Dianetics contributed to their mental wellness

CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceutical and Vanotech Ltd. today announced the successful completion of a Phase 2b clinical trial evaluating KH607...

Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study...

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- Guidelight Health today announced the launch of Prism, a specially developed LGBTQIA+ affirming Intensive Outpatient Program (IOP) for adults, expanding...

InStride reports 97% patient improvement in 2026, doubling enrollment and expanding across 5 East Coast markets while maintaining strong clinical results.